1.19
0.03 (2.16%)
| Penutupan Terdahulu | 1.16 |
| Buka | 1.19 |
| Jumlah Dagangan | 2,788,139 |
| Purata Dagangan (3B) | 4,380,428 |
| Modal Pasaran | 346,056,736 |
| Harga / Jualan (P/S) | 67.42 |
| Harga / Buku (P/B) | 20.00 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2025 - 11 Aug 2025 |
| Margin Operasi (TTM) | -979.14% |
| EPS Cair (TTM) | -0.210 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 46.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 199.97% |
| Nisbah Semasa (MRQ) | 2.60 |
| Aliran Tunai Operasi (OCF TTM) | -50.90 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -27.58 M |
| Pulangan Atas Aset (ROA TTM) | -61.33% |
| Pulangan Atas Ekuiti (ROE TTM) | -248.97% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Ocugen, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.38 |
|
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA"). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.60% |
| % Dimiliki oleh Institusi | 26.48% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Gmt Capital Corp | 31 Mar 2025 | 4,153,798 |
| Rinkey Investments | 31 Mar 2025 | 1,164,506 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 7.00 (HC Wainwright & Co., 490.72%) | Beli |
| 7.00 (Chardan Capital, 490.72%) | Beli | |
| Median | 7.00 (490.72%) | |
| Purata | 7.00 (490.72%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 0.700 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 12 May 2025 | 7.00 (490.72%) | Beli | 0.700 |
| HC Wainwright & Co. | 12 May 2025 | 7.00 (490.72%) | Beli | 0.700 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |